Skip to main content

Clinical trial EPIK-O

A Phase III, multi-center, randomized (1:1), open-label, activecontrolled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer (EPIK-O / CBYL719K12301)

Organ Ovary
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Novartis
EudraCT Identifier 2019-004682-40
Last update